Cenicriviroc 150 mg
Idiopathic Pulmonary Fibrosis
Clinical trials
1
Developer
Tobira Therapeutics, Inc.
Overview
Cenicriviroc 150 mg is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis. It appears in 1 tracked IPF clinical trial.
Cenicriviroc 150 mg clinical trials
Explore related
Medical disclaimer. This page summarizes research about Cenicriviroc 150 mg for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.